Mr. Molaei, CEO of the knowledge-based pharmaceutical company Faran Shimi, announced the company’s plan to reach $5 million in exports by the end of 2025.
According to the Public Relations Department of Golrang Pharmaceutical Group, Mr. Molaei made the announcement during an interview with Fana News Media at Pharmex 2025, highlighting the company’s achievements and future strategies in pharmaceutical production and global market expansion.
Robust Infrastructure for Sustainable Growth
Mr. Molaei emphasized Faran Shimi’s advanced production capabilities: “Our company operates three dedicated production lines: extraction, active pharmaceutical ingredient (API) manufacturing, and finished pharmaceutical products. Two API production lines meet international GMP standards. In addition, we’ve established a 2,400-square-meter compliant pharmaceutical warehouse, along with an energy facility built with an investment of over approximately $2 million — both vital to sustaining our operational growth.”
Export Milestones and Global Outlook
Faran Shimi recorded $1.7 million in foreign exchange export revenue and $2.5 million in domestic export revenue last year. Building on this performance, the company aims to reach $5 million in total exports in 2025 by leveraging advanced technologies, state-of-the-art infrastructure, and a highly skilled workforce.
“Our strategy is based on expanding export markets while relying on domestic expertise,” Mr. Molaei said. “We are optimistic about the future of Iran’s pharmaceutical industry and are committed to increasing the country’s share in the global drug market.”